Applied Immune Technologies

A drug development company specializing in T-cell-receptor-like (TCRL) antibodies for therapeutic and diagnostic applications.

Health Tech & Life Sciences
Acquired by Adicet Bio
Acquired Haifa, Israel Founded 2006
Last updated 2026-07-23
Total raised
$4.4M
Last: Undisclosed Round 2010-04
Stage
Acquired
Founded
2006
Headcount
1-10
HQ
Haifa, Israel
Sector
Health Tech & Life Sciences

About

Applied Immune Technologies (AIT) is a drug development company based in Haifa, Israel, specializing in T-cell-receptor-like (TCRL) antibodies for therapeutic and diagnostic applications in a variety of cancer, viral, and autoimmune diseases. The company also focuses on the identification and validation of novel therapeutic targets. AIT's core technology platforms encompass the identification and validation of novel MHC-based targets, as well as the development of therapeutic human recombinant TCRL antibodies. AIT also established Epitarget™, a proprietary technology to identify and validate novel disease-specific peptide targets.

Funding history · 2 rounds · $4.4M total

2010-03
A Round $4.0M
★ Pontifax
2008-06
Grant $400K

Headcount over time

From 126 (2018-06) to 2 (2024-08) · -124 (-98%) · 2 points · source: Finder history + radar grounding
1260 2018-06 2024-08

Q&A

What is Applied Immune Technologies' primary focus?
Applied Immune Technologies (AIT) is a drug development company specializing in T-cell-receptor-like (TCRL) antibodies for therapeutic and diagnostic applications in various cancer, viral, and autoimmune diseases. The company also focuses on identifying and validating novel therapeutic targets.
When was Applied Immune Technologies founded?
Applied Immune Technologies was founded in February 2006.
What is the current status of Applied Immune Technologies?
Applied Immune Technologies was acquired by Adicet Bio in January 2016 and is currently inactive.
How much funding has Applied Immune Technologies raised in total?
Applied Immune Technologies has raised a total of $4,400,000.
Which investors participated in Applied Immune Technologies' funding rounds?
Applied Immune Technologies received funding from the Office of the Chief Scientist and Pontifax.
What is the employee count for Applied Immune Technologies?
Applied Immune Technologies has 1-10 employees.
Who is a founder of Applied Immune Technologies?
Aya Yakobovitz, Ph.D. is a founder, director, and senior strategic advisor at Applied Immune Technologies.

Team · 2

Prof. Yoram Reiter
Founder · Founder
Mira Peled-Kamar
Founder · Chief Executive Officer

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 Patents

Tags

viral-diseasescancerantibodiesbiotechnologybiopharmaceuticaltherapeuticsdiagnosticsautoimmune-diseasespatientsdoctors
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitetcrl.co.il
LinkedInlinkedin.com/company/6951128

Identifiers & details

Legal nameApplied Immune Technologies Ltd.
Founded2006-2
Status reasonAcquired (Inactive) by Adicet Bio on Jan 2016 - closed due to acquisition

Acquisitions & public offerings

Acquired by Adicet Bio 2016-01

Radar intelligence

Patents

EPO22

Web history (Wayback)

Domaintcrl.co.il

Certificate / subdomain footprint

Subdomains2

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)513800649
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2006-02-21
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2026
Active charges / liens0
Registry events3 — other (1), violation (1), annual_report (1)
Registered addressאידר 15 חיפה

Recent registry events

DateEvent
2026-02-18עדכון כתובת ו/או מען דיגיטלי
2026-06-12עדכון הפרה
2026-06-10דו~ח שנתי